Patients with severe/critical COVID 19 who will receive 500 ml of Convalescent plasma (CP), obtained from donors who have been recovered from SARS-CoV-2 infection.
These patients may or may not get other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc

Patients with severe/critical COVID 19 who will not receive Convalescent plasma (CP). These will be those who were recruited during the period before CP becomes available or for whom no compatible CP is available.
These patients will receive one or more of the other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc

Covid19

500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.

Convalescent Plasma (CP)

This will include drugs like steroids, tocilizumab, azithromycin and supportive care

Drugs and supportive care

Aga Khan University Hospital

Convalescent Plasma Treatment in COVID-19

Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan

Decrease length of stay in hospital , Decrease length of stay in ICU/special care unit

Any adverse event after the transfusion of Convalescent plasma which include TRALI, TACO, allergic reaction, anaphylaxis.

Modified from WHO scale. It includes clinical status of patient in terms of respiratory support needed.

Time to improvement in serum ferritin levels after intervention

Time to improvement in serum Procalcitonin levels after intervention

Time to improvement in C-Reactive protein levels after intervention

Time to improvement in D-Dimer levels after intervention

Time to improvement in complete blood count after intervention

Time to improvement in chest X-Ray findings after intervention

syphilis/obrzęk

Convalescent Plasma Treatment in COVID-19

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo